Versigent (NYSE:VGNT – Get Free Report) was upgraded by analysts at Argus to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.
VGNT has been the topic of several other research reports. UBS Group decreased their price objective on Versigent from $58.00 to $55.00 and set a “buy” rating on the stock in a research note on Thursday, July 9th. Wolfe Research began coverage on Versigent in a research note on Thursday, April 30th. They set an “outperform” rating and a $53.00 price objective for the company. Fox Advisors raised shares of Versigent to a “strong-buy” rating in a report on Tuesday, April 7th. Oppenheimer set a $50.00 target price on shares of Versigent in a research note on Tuesday. Finally, BNP Paribas Exane assumed coverage on shares of Versigent in a research note on Tuesday, April 28th. They set an “outperform” rating and a $41.00 target price on the stock. Four research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $49.67.
Get Our Latest Stock Analysis on Versigent
Versigent Trading Up 2.8%
Recommended Stories
- Five stocks we like better than Versigent
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
- 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for Versigent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versigent and related companies with MarketBeat.com's FREE daily email newsletter.
